Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

Clinical trial NCT04863248 · TERMINATED

Trial details

NCT number: NCT04863248
Sponsor: G1 Therapeutics, Inc.
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Non-Small Cell Lung Cancer NSCLC Lung Cancer

Start date: 2021-04-30
Primary completion: 2022-02-02
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.